NCT04472897View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants

PHASE1TerminatedINTERVENTIONAL

Enrollment

92

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

November 6, 2024

Study Completion Date

November 6, 2024

Conditions

Tuberculosis

Interventions

DRUG

GSK2556286

GSK2556286 will be administered.

DRUG

Placebo

Placebo will be administered

Trial Locations (2)

9713 AG

GSK Investigational Site, Groningen

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT04472897 - A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter